CD274 and non-small cell lung carcinoma: A total of 8 articles were included in this meta-analysis (Figure S1, Supplemental Digital Content 1, http://links.lww.com/MD/H297), including 7 were conducted in multi-centers, 5 studies in NSCLC patients, 3 studies using PD-L1 inhibitor Atezolizumab, 6 studies using PD-1/PD-L1 inhibitors monotherapy.